Amgen Stock: Bet On Its Breakthrough Drug (NASDAQ:AMGN)

Investment Thesis

In this analysis of Amgen Inc. (NASDAQ:AMGN), I will dive into a biotech frontrunner renowned for its innovative therapies. As I comprehend and relay my perspective on the company’s journey and scrutinize its financial health, you will be guided through a piece describing and highlighting the recent news associated with Amgen and its impact on the stock going forward. From its intuitive drug pipeline to company acquisitions, we will unpack the elements that emphasize my thesis in Amgen as a solid investment. Expect a balanced article with deep exploration of both the bright prospective drugs, like tarlatamab, and the risks of the sector itself, including the latest impact of new legislation. In essence, this analysis is a comprehensive view that intertwines the variety of factors that underlie my buy recommendation for Amgen.

Rating: Buy

Background

Amgen Inc., a biotechnology company, is known for its focus on researching and developing innovative therapies in areas with significant unmet medical needs. Currently, the company specializes in the fields of oncology, cardiovascular disease, bone health, neuroscience, nephrology, and inflammation. Amgen’s approach involves harnessing the power of cutting-edge science, particularly in biologics, to create treatments that improve health outcomes. Their portfolio includes both novel drugs and biosimilars, aiming to provide a range of options for patients and healthcare professionals. Committed to scientific discovery, Amgen invests heavily in research and development, striving to push the boundaries of biotechnology to address complex and serious illnesses. The company’s global presence, marked by collaboration with healthcare communities and adherence to rigorous ethical standards, reflects its mission to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.

Current Financials

In Q3 2023, Amgen Inc. showcased strong financial health, underlined by a 4% increase in total revenues and a 6% rise in earnings per share compared to the previous year. This performance is notably propelled by an 11% global volume growth, marking the fourth consecutive quarter of substantial growth (I am a fan of momentum). As the stock recently has trended higher (6 month time-frame) due to historical data, such as the volume growth, we understand that the stock will continue to increase until an external piece of news/investor moat causes a shift in the trend (as you can tell I’m directly depicting Newton’s Law). Momentum is our friend and I recommend you look over the table below.

Click to enlarge

Moreover, the strategic acquisitions of Horizon Therapeutics and ChemoCentryx have notably diversified Amgen’s portfolio, particularly strengthening its presence in rare diseases. Key products like Repatha, EVENITY, and Tezspire have been pivotal in driving sales, demonstrating Amgen’s ability to effectively penetrate and expand in significant market segments. Furthermore, the company’s promising pipeline, including potential first-in-class oncology assets and innovative therapies like maridebart cafraglutide in obesity, suggests a trajectory of continued growth and market leadership.

Amgen’s management holds a revolving confident outlook on the company’s future, illustrating a strong commitment to scientific innovation and addressing unmet medical needs. However, the challenges inherent in the biotechnology sector, such as the necessity for ongoing innovation and adapting to dynamic market demands, are acknowledged (but I believe Amgen is taking this head on successfully).

Despite these challenges, Amgen’s solid financials, strategic growth initiatives, and persistent focus on innovation solidify the recommendation for a buy. The company’s proficient navigation in the complex biotech market and its sustained leadership in innovation are key factors in its ongoing success and appeal as an investment.

Ultimately, Amgen’s current financial state coupled with its strategic initiatives and future outlook present a compelling case for investment. The company’s focus on diversification through strategic acquisitions, a both innovative and veteran drug pipeline, and consistent growth across key products positions it well for sustained success. While acknowledging the risks associated in the biotech sector, I believe Amgen demonstrates the ability to manage these challenges, which boosts my confidence in its potential for continued growth and profitability: indeed a buy recommendation.

Tarlatamab’s Priority Review

The FDA granting priority review to Amgen’s tarlatamab application, an investigational therapy targeting small cell lung cancer (SCLC), is a pivotal development for the company. This status is significant because it accelerates the review process of tarlatamab, a potentially groundbreaking treatment in Amgen’s pipeline. The FDA reserves priority review for drugs that, if approved, would significantly improve the treatment, diagnosis, or prevention of serious conditions; the first type of therapy for a major solid tumor. This designation not only highlights the potential clinical importance of tarlatamab but also underscores Amgen’s capability in developing impactful therapies (and potentially first of its kind).

From an investment perspective, this news is highly encouraging and could be a huge catalyst. The priority review suggests a strong confidence in tarlatamab’s efficacy and safety profile, potentially leading to a quicker path to market. Faster market entry can mean an early revenue stream, which is crucial for recouping research and development costs and further investing in the pipeline. Additionally, it positions Amgen as a leader in innovation if they can be the first (they would be), especially in the high-stakes area of oncology.

Moreover, the successful development and approval of tarlatamab could significantly enhance Amgen’s portfolio, particularly in the oncology segment, which is a key growth driver in the pharmaceutical industry. It also reflects positively on Amgen’s research capabilities and its strategy of focusing on cutting-edge, high-impact therapeutic areas.

Ultimately, this priority review could be a big deal, and not only reinforces the company’s position in the biopharmaceutical sector but also supports my rating and outlook of the company. This simply suggests the potential for significant growth and value generation for Amgen in the near future. This new development is a clear indicator of delivering both clinical and economic value, solidifying my confidence in its long-term investment upside.

Change in Leadership, RBC Upgrade, Dividend Increase

Amgen’s recent executive appointments, as announced, are a strategic move that significantly reinforces my buy thesis. These appointments demonstrate Amgen’s commitment to fostering innovation and leadership amongst its management within the biopharmaceutical industry. By bringing in fresh perspectives and expertise, Amgen is positioning itself to effectively navigate the complex challenges of drug development and market dynamics. This proactive approach in strengthening its leadership team is a clear indication of the company’s dedication to maintaining its competitive edge and driving future growth, which, in my opinion, makes Amgen a more attractive investment option.

The upgrade of Amgen’s stock by RBC Capital Markets is a significant endorsement of the company’s strong market position and future prospects. This upgrade reflects confidence in Amgen’s strategic initiatives and its pipeline’s potential. It’s a solid factor that reinforces my buy thesis, as it represents a positive shift in market perception and acknowledges the company’s ongoing efforts to innovate and expand its product offerings. This upgrade from a respected financial institution adds an extra positive layer to Amgen’s investment appeal (for those not trying to pursue a contrarian edge).

Also, Amgen’s announcement of a dividend increase to $2.25 per share for the first quarter of 2024 strongly supports my rating as this is always a positive element for the income-focused investors reading. This increase signals the company’s financial strength and confidence in its future performance. It’s a clear message to investors about Amgen’s commitment to delivering value to shareholders, which emphasized my view that Amgen remains a solid investment with potential upside.

Risks: An Evolving Industry, Reliance on Veteran Drugs, and the Inflation Reduction Act

In assessing the investment potential of Amgen, it’s vital to consider potential risks. Firstly, Amgen operates in the highly competitive biotech industry, where rapid innovation is crucial. This volatile industry faces constant and intense competition due to the ability of newer, more effective treatments that can quickly overshadow existing products. Failure to keep pace with scientific advancements or delays in drug development can impact the company’s market position and revenue streams. Secondly, Amgen is relying much on some key products like Repatha and EVENITY along with a couple others, which does pose a risk. Murdo Gordon, executive VP, stated in the earning call:

“Starting with our general medicine business, which includes Repatha, Prolia, Evenity and Aimovig. Overall revenue for these four products grew 21% year-over-year in the third quarter, driven by 20% volume growth.” – Q3 Earnings Call

Any disruptions in these products, whether from competition, production issues, or changes in healthcare policies, could affect financial performance. Contrarily, they did note in the call as well that there is still room for growth amongst patients (so they will continue to provide investments) with such veteran drugs in their pipeline, which I thought was a reassuring attribute.

Additionally, navigating the shifting landscape of pharmaceuticals presents a multitude of risks, some more apparent than others. Based on the December 14th release from the Biden-Harris Administration, for a company like Amgen, the Inflation Reduction Act introduces a complex challenge. On the one hand, the act aims to curtail the rampant price hikes that have burdened seniors for years, and on the surface, this is a win for the consumer. Yet, the requirement for pharmaceutical companies to pay rebates to Medicare if they raise drug prices faster than inflation adds a financial strain. The impact on Amgen’s bottom line could be significant, especially considering the new list of 48 Medicare Part B drugs that raised their prices faster than inflation. And according to the Seeking Alpha news article, products from the following company’s (along with some others) could be subject to inflation penalties: Amgen, AbbVie (NYSE:ABBV), and Pfizer (NYSE:PFE).

The data is illustrating that, over the last year, some medications have consistently outpaced inflation every quarter. So, this isn’t just about adjusting numbers on a balance sheet; it reflects a fundamental shift in how companies like Amgen will have to approach pricing strategies and revenue projections now and going forward. Moreover, the act’s provision to negotiate drug prices directly with Medicare, starting in 2026, could further compress profit margins.

While these measures aim to make healthcare more affordable for the public, they inject a dose of uncertainty into the pharmaceutical industry. With that, investors should be cautious of this news as I will be monitoring it going forward, and I recommend others do so, too. The potential for reduced revenues is real, and the pharma sector’s historical resistance to such reforms suggests a rocky road ahead. For Amgen, a company that has likely benefited from the absence of such legislation until now, the Inflation Reduction Act could herald a new era of tighter regulation and financial scrutiny. It’s a balancing act between public good and private wealth, and only time will tell how well Amgen, and indeed the entire pharma industry, will adapt to these changes.

Despite these risks, Amgen’s diversified portfolio, strong R&D pipeline, and strategic acquisitions provide a buffer against these challenges. The company’s track record of navigating complex regulatory environments and adapting to market changes provides extensive confidence in its resilience and ability to continue delivering shareholder value. Therefore, while these risks are noteworthy, Amgen’s strengths and proactive strategies present a compelling case for an investment.

Is Amgen A Value Play?

Now looking beyond the buzz and catalysts, let’s dive into the hard numbers, which will give us a clearer picture of what we’re truly investing in. There are a few metrics I would like to focus on, starting with the Price to Earnings (P/E) ratio. A forward P/E of 19.89, as reflected in the stock we’re analyzing, not only undercuts the sector median of 29.09 but also carries a Seeking Alpha grade of B+. This suggests a valuation that’s more reasonable in terms of growth expectations, which for investors like us, spells opportunity.

Moving onto the Price to Sales (fwd) ratio, a similar story continues to be read. The figure sits at 5.24, which again is comfortably compared to the sector’s 3.96 median. Though the grade here is a ‘C’, indicating average performance amongst its peers, it’s essential to highlight that this metric leans towards the stock being fairly on par in terms of sales, offering another layer to the investment thesis.

Next, Price to Cash Flow (fwd) stands at 13.08, showcasing that the stock is generating cash at a rate that’s appealing when stacked against a sector median of 16.91. With a ‘B’ grade from Seeking Alpha, it’s clear that on a cash flow basis, the stock is not only healthy but also potentially overlooked by the market.

Click to enlarge

Also, something I think that is worth mentioning is the Quant Rating. The score given to Amgen Inc. was 4.54 (a strong buy based on the scale), which was derived from the following factors: valuation, growth, profitability, momentum and revisions. This is depicted below.

But I think what is truly sweetening about Amgen is the dividend. Based on the trailing-twelve-months, it stands at a solid 3.09%—significantly over the sector median of 1.63%—and seems like a ‘cherry on top,’ to me. This signals the company’s confidence in its ability to generate and distribute wealth to its shareholders consistently, a key element especially in the biotechnology field.

What story do these numbers tell us about the company? Aside from its stable fundamentals, it suggests a security that, compared to its peers, might just be undervalued— potentially great upside in this crowded market. For an investor seeking a blend of growth, value, and income, this stock checks all the boxes. After all it is all about finding a stock that’s positioned to outperform while still offering a margin of safety. And Amgen is most definitely an opportunity worth exploring.

The Key Takeaway

With the conclusion of my analysis on Amgen, it becomes clear that the company stands high on my list of biotechnology investments. Viewing their backdrop of innovation and strategic market navigation, Amgen shines with a solid pipeline and strong financials. I’ve conveyed many of the risks within the industry and also the stocks potential, which to me revealed a story of resilience and upward growth. My assessment resonates with a belief in Amgen’s capability to transcend amongst its sector, endorsing an investment with what I interpret and believe is a bright future.